Grabar Law Office Investigates Claims on Behalf of Shareholders of Co-Diagnostics, Inc. (CODX)

Philadelphia, Pennsylvania--(Newsfile Corp. - August 23, 2023) - A securities fraud class action complaint alleges that the company, through certain of its officers and directors, repeatedly touted the Logix Smart™ COVID-19 Test, reassuring investors about the demand for the product. The Complaint further alleges that, at the same time, Defendants failed to disclose that: (1) demand for the Logix Smart™ COVID-19 Test had plummeted throughout the quarter ended June 30, 2022, and (2) as a result, Defendants' positive statements about the demand for its Logix Smart™ COVID-19 Test lacked a reasonable basis.

If you are a current Co-Diagnostics (NASDAQ: CODX) shareholder who has held shares since on or before May 12, 2022, you may be able seek corporate reforms, the return of funds expended defending litigation back to company coffers, and a court approved incentive award if appropriate.

If you would like to learn more about this matter at no cost to you, visit https://grabarlaw.com/the-latest/codx-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.

Attorney Advertising Disclaimer
These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/178247